L-Cycloserine
- Generic Name
- L-Cycloserine
- Brand Names
- Seromycin
- Drug Type
- Small Molecule
- Chemical Formula
- C3H6N2O2
- CAS Number
- 339-72-0
- Unique Ingredient Identifier
- AK7DRB7FMO
- Background
Antibiotic substance produced by Streptomyces garyphalus.
- Indication
本品与其他抗结核药联合，用于经一线药物（如吡嗪酰胺、链霉素、异烟肼、利福平和乙胺丁醇）治疗失败的患者。本品还可用于治疗非结核分枝杆菌感染如鸟复合分枝杆菌病的治疗。
- Associated Conditions
- Pulmonary Tuberculosis (TB), Tuberculosis, Extrapulmonary, Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection
- Associated Therapies
- -
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 56
- Registration Number
- NCT01733030
- Locations
- 🇺🇸
University of MInnesota, Minneapolis, Minnesota, United States
The Use of D-Cycloserine to Augment CBT for Pediatric OCD
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 26
- Registration Number
- NCT01687140
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
D-cycloserine Augmented CBT for Panic Disorder
- Conditions
- Interventions
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 33
- Registration Number
- NCT01680107
- Locations
- 🇬🇧
Department of Psychiatry, University of Oxford, Oxford, United Kingdom
D-Cycloserine as an Adjunct to Internet-CBT for OCD
- Conditions
- Interventions
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Christian Rück
- Target Recruit Count
- 128
- Registration Number
- NCT01649895
- Locations
- 🇸🇪
M46 Huddinge sjukhus, Internetpsykiatrienheten/mottagningen för tvångssyndrom, Stockholm, Sweden
Improving Learning-based Treatment of Cocaine Dependence With Medication
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 52
- Registration Number
- NCT01526538
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Exploring Learning and Unlearning of Fear
- Conditions
- Interventions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Registration Number
- NCT01512316
- Locations
- 🇧🇪
Catholic University Leuven, Departement of Radiology, Leuven, Belgium
Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Roger K. Pitman, MD
- Target Recruit Count
- 34
- Registration Number
- NCT01490697
- Locations
- 🇺🇸
Dallas VA, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
- Conditions
- Interventions
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT01450306
- Locations
- 🇺🇸
Institute of Living/Hartford Hospital, Hartford, Connecticut, United States
D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)
- Conditions
- Interventions
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 142
- Registration Number
- NCT01411774
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
🇺🇸University of South Florida, Saint Petersburg, Florida, United States
2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD
- Conditions
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT01404208
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.